Delivery Order SPE2DR25D3012-SPE2DR26F4E3C
- Not listed
- The Defense Logistics Agency awarded a $10,641.07 delivery order to AmerisourceBergen Drug Corp for 30-count bottles of Tagrisso 40 mg tablets, with an ultimate completion date of June 2, 2025. This is a firm fixed-price, non-set-aside contract awarded on May 9, 2025, with performance at the company's Conshohocken, Pennsylvania facility. Tagrisso (osimertinib) is a targeted cancer therapy used primarily in treating non-small cell lung cancer, reflecting the breadth of pharmaceutical products...
- The Defense Logistics Agency awarded a delivery order valued at $21,325.14 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on June 2, 2025, with a completion date of June 24, 2025. This firm fixed-price delivery order represents a non-competitive set-aside and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Tagrisso (osimertinib) is a targeted cancer therapy used primarily in the treatment of non-small...
- The Defense Logistics Agency awarded a delivery order valued at $21,325.14 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units). This firm fixed-price, competitively awarded delivery order was issued on July 22, 2025, with an ultimate completion date of August 12, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, AmerisourceBergen's corporate headquarters and primary distribution center. Tagrisso (osimertinib) is an advanced...
- The Defense Logistics Agency awarded a delivery order valued at approximately $128K to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units). This competitively awarded, firm fixed-price contract contains no set-aside designation and is scheduled for completion by October 16, 2025. The contract was awarded on September 24, 2025, with performance occurring at the contractor's corporate headquarters in Conshohocken, Pennsylvania. Tagrisso (osimertinib) is a targeted...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a contract ceiling value of $10,662.57. This firm fixed-price delivery order, which is expected to be completed by October 3, 2025, represents a non-set-aside competitive award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used...
- The Defense Logistics Agency awarded a $42,650.28 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 7, 2025, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used in the treatment of certain lung cancers, and this award...
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages). This competitive award, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance of this contract will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a ceiling value of $10,662.57 and a firm fixed price structure. This delivery order, issued under a competitive, non-set-aside procurement, is scheduled for completion by October 16, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy...
- The Defense Logistics Agency awarded a delivery order valued at $42,650.28 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on September 12, 2025, with completion expected by October 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tagrisso is an oncology medication used in the treatment of non-small cell lung cancer,...
- The Defense Logistics Agency awarded a $31,987.71 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by October 10, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, consistent...
- SPE2DR25D3012Indefinite Delivery Contract
- SPE2DR25D3012-SPE2DR26F4E3CDelivery Order
The Defense Logistics Agency awarded a $12.44K delivery order to AmerisourceBergen Drug Corp for 30-count bottles of Tagrisso 80 mg tablets, with performance at the contractor's Conshohocken, Pennsylvania facility. This non-competitive, firm fixed-price delivery order was awarded on January 5, 2026, with an ultimate completion date of January 27, 2026. Tagrisso (osimertinib) is a targeted cancer therapy used primarily in lung cancer treatment, reflecting the critical pharmaceutical support that DLA Medical Supply Chain provides to military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999 ceiling and extends through December 2026. As a prime pharmaceutical vendor under this global contract vehicle, AmerisourceBergen supplies a comprehensive range of medications, vaccines, medical devices, and specialty pharmaceuticals to support Defense Health Agency operations and other federal healthcare programs worldwide. The company's established position as a major federal pharmaceutical distributor, combined with its capability to fulfill orders across multiple therapeutic domains, demonstrates its critical role in sustaining military medical readiness.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.4k | 1/4/26 |